Dr. Souri Kumar Felix

Dr. Yogesh Kulkarni

Assistant Professor, Pharmaceutical Sciences

Location: Flemmie Kittrell Hall 215

Phone: 757-727-5543

E-mail: yogesh.kulkarni@hamptonu.edu

Expertise: Proteomics, Breast Cancer, Natural Products

Dr. Yogesh Kulkarni joined the School of Pharmacy faculty at Hampton University in August of 2014. Dr. Kulkarni is the course instructor for Physiological Chemistry (PHA 311), Biostatistics & Epidemiology (PHA 332), Immunology and Microbiology (PHA 423) and an instructor & course coordinator for Drug & Disease Management (DDM) courses, DDM VII (PHA 586) and DDM VIII (PHA 588). Additionally, Dr. Kulkarni offers an elective course Alternative Medicine (PHA 572).

Dr. Kulkarni’s research interests are high-throughput cancer proteomics, cancer drug resistance, and investigating the therapeutic potential of natural products in cancer therapy.

Education

Ph.D. (Biomedical Engineering), Louisiana Tech University, Ruston, LA, 2007

B.E. (Instrumentation Engineering), University of Mumbai, 1999

Honors and Awards

2017 Department of Pharmaceutical Sciences Professor of the Year, Hampton University School of Pharmacy

2015 Induction into Rho Chi Honor Society

2013 Induction into Sigma Xi Scientific Research Society

2010 Van Liere Research Award, West Virginia University

Grantsmanship

SC3GM122655       09/11/2017 – 08/31/2021

National Institute of Health/National Institute of General Medical Sciences

Title: Reversing Resistance to PARP-Inhibitor in Triple Negative Breast Cancer

Role: Principal Investigator    Amount: $444,000

Hampton University Faculty Grant      10/19/2015 – 04/29/2016

Title: Molecular Profiling of PARP-Inhibitor Resistant Triple Negative Breast Cancer

Role: Principal Investigator     Amount: $4,500

Dissemination of Research

Scientific Papers

* denotes under-graduate researcher, Ψ denotes equal contribution Refereed Publications (Total citations: 78 (Google scholar); h-index: 5) Listed after each article: Number of citations as of April, 2017 {Google Scholar unless noted} [Journal impact factor 2015]

  1. Kulkarni YM, Yakisich JS, Azad N, Venkatadri R, Kaushik V, O’Doherty G, Iyer AKV. Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells. Tumour Biology. 2017 Jun;39(6):1010428317705331. doi: 10.1177/1010428317705331. {0}[2.9]
  2. Kaushik V, Yakisich JS, Azad N, Kulkarni YM, Venkatadri R, Wright C, Rojanasakul Y, Iyer AK. Anti-Tumor Effects of Cardiac Glycosides on Human Lung Cancer Cells and Lung Tumorspheres. Journal of Cellular Physiology. 2016 Sep 23. doi: 10.1002/jcp.25611. Epub ahead of print {2}[4.1]
  3. Yakisich JS, Azad N, Venkatadri R, Kulkarni YM, Wright C, Kaushik V, and Iyer AK. Formation of Tumorspheres with Increased Stemness without External Mitogens in a Lung Cancer Model. Stem Cells International 2016:5603135. doi: 10.1155/2016/5603135. Epub 2016 Jan 6 {4}[3.7]
  4. Yakisich JS, Azad N, Venkatadri R, Kulkarni YM, Wright C, Kaushik V, O’Doherty G, and Iyer AK. Digitoxin and its synthetic analog Monod have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel. Oncology Reports. 2016 Feb;35(2):878-86. doi: 10.3892/or.2015.4416. Epub 2015 Nov 12 {5}[2.5]
  5. Kulkarni YM, Dutta S, Iyer AK, Venkatadri R, Kaushik V, Ramesh V, Wright CA, Semmes OJ, Yakisich JS, Azad N. A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis. Proteomics. 2016 Jan;16(1):33-46. doi: 10.1002/pmic.201500171. Epub 2015 Nov 24 {5}[4.0]
  6. Kulkarni YM, Kaushik V, Azad N, Wright C, Rojanasakul Y, O’Doherty G, Iyer AK. Autophagy-Induced Apoptosis in Lung Cancer Cells By a Novel Digitoxin Analog. Journal of Cellular Physiology. 2016 Apr; 231(4):817-28. doi: 10.1002/jcp.25129 {4}[4.1]
  7. Wright C, Iyer AK, Kulkarni YM, Azad N. S-Nitrosylation of Bcl-2 Negatively Affects Autophagy in Lung Epithelial Cells. Journal of Cellular Biochemistry. 2016 Feb;117(2):521-32. doi: 10.1002/jcb.25303 {3}[3.4]
  8. Iyer AK, Ramesh V, Castro CA, Kaushik V, Kulkarni YM, Wright CA, Venkatadri R, Rojanasakul Y, Azad N. Nitric Oxide Mediates Bleomycin-Induced Angiogenesis and Pulmonary Fibrosis via Regulation of VEGF. Journal of Cellular Biochemistry. 2015 Nov;116(11):2484-93. doi: 10.1002/jcb.25192 {12}[3.4]
  9. Klinke DJ 2nd, Kulkarni YM, Wu Y, Byrne-Hoffman C. Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profiling of three cell models. Biotechnology and Bioengineering 2014 Biotechnol Bioeng. 2014 Sep;111(9):1853-63 {15}[4.2]
  10. Kulkarni YMΨ, Liu CΨ, Qi Q, Zhu Y, Klinke DJ 2nd, and Liu J. Differential proteomic analysis of caveolin-1 KO cells reveals Sh2b3 and Clec12b as novel interaction partners of caveolin-1 and capns1 as potential mediator of caveolin-1-induced apoptosis. Analyst 2013 Nov 21;138(22):6986-96 PMID: 24091439 {2}[4.0]
  11. Kulkarni YM, Chambers E, McGray AJR, Ware JS*, Bramson JL, and Klinke DJ 2nd. A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model. Integrative Biology 2012, 4(8):925-36 PMID: 22777646 {16}[3.6]
  12. Kulkarni YM and Klinke DJ 2nd. Protein-based identification of quantitative trait loci associated with malignant transformation in two HER2+ cellular models of breast cancer. Proteome Sci 2012, 10(1):11. PMID: 22357162 {7}[1.7]
  13. Kulkarni YM, Suarez V, and Klinke DJ 2nd. Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling. BMC Cancer 2010, 10:291 PMID: 20550684 {14}[3.2]

Conference Proceedings and Presentations

  1. Kulkarni YM, Neelam Azad, Vivek Kaushik, Juan Sebastian Yakisich, Rajkumar Venkatadri, Clayton Wright, Yon Rojanasakul, George O’Doherty, Anand Krishnan V Iyer. “Metabolomic profiling of cell death in human lung cancer cells by a novel digitoxin analog”, Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR); 2016 Apr 16-20; New Orleans, LA.
  2. Kulkarni YM, Vivek Kaushik, Raj Venkatadri, Clayton Wright, Juan Sebastian Yakisich, George O’Doherty, Neelam Azad, Anand Iyer. “Cardiac glycoside digitoxin and its monosaccharide analogue MonoD inhibit NFÎşB to induce apoptotic cell death in ER+ MCF7 and triple-negative MDAMB-468 breast cancer cells”, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia, PA.
  3. Clayton A. Wright, Anand Krishnan V. Iyer, Kulkarni YM, Neelam Azad. “S-nitrosylation of Bcl-2 negatively affects autophagy in malignantly transformed lung epithelial cells”, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia, PA.
  4. Rajkumar Venkatadri, Clayton Wright, Vivek Kaushik, Kulkarni YM, Juan Sebastian Yakisich, Anand Krishnan V. Iyer, Neelam Azad. “Role of microRNAs in resveratrol induced breast cancer cell death”, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia, PA.
  5. Kulkarni YM, Vivek Kaushik, Clayton Wright, George O’Doherty, Neelam Azad, Anand Iyer. “MonoD, a novel analogue of digitoxin, induces superoxide mediated autophagic cell death in H460 lung cancer cells”, Proceedings of the 105th Annual Meeting of the American Association for Cancer Research (AACR); 2014 Apr 5-9; San Diego, CA.
  6. Azad N, Kulkarni YM, Rojansakul Y, O’Doherty G and Iyer AK. “Anti-tumorigenic Effects of a Novel Digitoxin Analogue”, Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR); 2013 Apr 6-10; Washington, DC.
  7. Kulkarni YM, Alexander K, Wu Y and Klinke DJ 2nd. “Inferring Tumor-Immune Interaction Networks Via Unbiased Secretome Profiling”, American Institute of Chemical Engineers (AIChE) National Meeting, Pittsburgh, PA, October 2012.
  8. Klinke DJ 2nd, Kulkarni YM, Chambers E, McGray AJR, Ware JS* and Bramson JL. “B16 melanoma inhibits cellular response to Interleukin-12 via multiple mechanisms including paracrine action of Wnt-inducible Signaling Protein-1”, American Association of Immunologists (AAI) Annual Meeting, Boston, MA, May 2012.
  9. Alexander A, Wu Y, Kaiser J, Kulkarni YM and Klinke DJ 2nd. “Characterizing and comparing secretome from breast cancer and normal human cell models”, American Chemical Society (ACS) National Meeting, San Diego, CA, March 2012.
  10. Kulkarni YM and Klinke DJ 2nd. “Inference of Predominant Pathways in Cancer: A Proteomic Study among Three Human Mammary Epithelial Cell Models”, American Institute of Chemical Engineers (AIChE) National Meeting, Minneapolis, MN, October 2011.
  11.  Kulkarni YM, Chambers E, McGray AJR, Ware JS*, Bramson JL and Klinke DJ 2nd. “Tumor-derived Wnt-inducible Signaling Protein-1 (WISP1) exhibits paracrine immunosuppression by inhibiting cellular response to Interleukin-12”, Cancer Immunology and Immunotherapy: Building on Success, Bethesda, MD, September 2011.
  12.  Kulkarni YM and Klinke DJ 2nd. “Identifying Secreted Biomarkers for Immune Evasion in Cellular Models of Cancer”, American Institute of Chemical Engineers (AIChE) National Meeting, Salt Lake City, UT, November 2010.
  13.  Kief KD*, Brundage KM, Kulkarni YM and Klinke DJ 2nd. “Assessing the Signal-to-Noise Characteristics for Two Transcription Factor Assays”, American Institute of Chemical Engineers (AIChE) National Meeting, Salt Lake City, UT, November 2010.
  14.  Ware JS*, Kulkarni YM and Klinke DJ 2nd. “Identifying biochemical cues secreted by malignant melanocytes that promote escape from immunoediting”, American Institute of Chemical Engineers (AIChE) National Meeting, Salt Lake City, UT, November 2010.
  15.  Klinke DJ 2nd, Kulkarni YM and Suarez, V. “Profiling Signaling Pathways Using Comparative Proteomics: An Illustrative Example From Breast Cancer”, American Institute of Chemical Engineers (AIChE) National Meeting, Nashville, TN, November 2009
  16.  Kulkarni YM, Suarez V and Klinke DJ 2nd. “Proteomics of Breast Cancer for Signal Pathway Profiling and Target Discovery”, Biomedical Engineering Society (BMES) Annual Meeting, Pittsburgh, PA, October 2009
  17.  Kief KD*, Brundage KM, Kulkarni YM and Klinke DJ 2nd. “Assessing the Signal-to-Noise Characteristics for Two Transcription Factor Assays”, Biomedical Engineering Society (BMES) Annual Meeting, Pittsburgh, PA, October 2009
  18.  Widmeyer J*,Kulkarni YM and Klinke DJ 2nd. “Proteomics-Based Secretome Analysis for Cancer Cell Biomarker Assay”, Biomedical Engineering Society (BMES) Annual Meeting, Pittsburgh, PA, October 2009
DONATE